Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 déc. 2025 09h15 HE | Source: Longeveron

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Longeveron granted Canadian patent for method of using stem cells to treat patients with aging-related frailty and also for the treatment of NIDCM.
12 nov. 2025 09h05 HE | Source: Longeveron

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Longeveron issued US patent for method of treating aging-related frailty in patients with inflammaging using its proprietary stem cell therapy.
01 nov. 2021 19h45 HE | Source: The Rosen Law Firm PA

LGVN SHAREHOLDER ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or...